Kindai University Hospital

Osaka, Osakasayama 589-8511

0 studies enrolling now · 8 studies all time

What they study most

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Idiopathic Pulmonary Fibrosis, Lung Diseases, Interstitial, Mesothelioma, Palmoplantar Pustulosis (PPP), Scleroderma, Systemic

Studies at this site

• A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) — Completed
• A Study to Test How Effective and Safe Different Doses of BI 655130 Are in Patients With a Moderate to Severe Form of the Skin Disease Palmoplantar Pustulosis — Completed
• A Trial to Evaluate the Safety of Long Term Treatment With Nintedanib in Patients With Scleroderma Related Lung Fibrosis — Completed
• Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity Impairment — Completed
• Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis — Completed
• A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis — Completed
• Nintedanib (BIBF 1120) in Mesothelioma — Stopped early
• BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation — Completed